
UTI Healthcare Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended)Download Report
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: BSE Healthcare Total Return IndexCheck Portfolio Overlap →
NAV: ₹401.84+0.78%
20 Nov 2026
Holdings Analysis
Equity, debt and cash allocation snapshot with market cap distribution for UTI Healthcare Fund Direct-Growth.
Market Cap Distribution
Large Cap (19.6%)
Mid Cap (37.0%)
Small Cap (43.4%)
Historical Asset Allocation
| Asset | 31 Oct 2026 | 30 Sep 2026 | 31 Aug 2026 | 31 Jul 2026 | 30 Jun 2026 | 31 May 2026 |
|---|---|---|---|---|---|---|
| Equity | 98.01% | 94.12% | 94.27% | 97.08% | 95.05% | 94.45% |
| Debt | 0.03% | 0.02% | 0.02% | 0.02% | 0.01% | 0.01% |
| Others (incl. cash) | 1.96% | 5.85% | 5.71% | 2.90% | 4.95% | 5.54% |
| Commodities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Real Estate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Portfolio Snapshot
No. of Securities
47
P/E Ratio
41.09
P/B Ratio
5.31
Top Holding %
7.44%
Top 5 Holdings %
28.18%
Top 10 Holdings %
46.57%
AUM
₹1,433 Cr
Expense Ratio
1.31%
Since Inception
16.58%
Max Drawdown
-0.27%
Alpha
0.92%
Sharpe Ratio
1.07
Top Portfolio Holdings by Weight
Latest portfolio holdings sorted by allocation weight. Includes instrument name, sector, number of shares, market value (₹ Cr) and percentage of net assets. Switch dates or categories using the controls below.
| Instrument | Sector | No. of Shares | Value (Rs. Cr) | Weight | Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 6,00,000 | 106.66 | 7.44% | -0.18%↓ |
| Divis Laboratories Ltd. | Healthcare | 94,707 | 92.62 | 6.46% | 0.31%↑ |
| Dr. Reddys Laboratories Ltd. | Healthcare | 6,12,629 | 82.83 | 5.78% | 0.55%↑ |
| Ajanta Pharma Ltd. | Healthcare | 1,75,000 | 61.4 | 4.29% | -0.53%↓ |
| Max Healthcare Institute Ltd. | Healthcare | 7,00,000 | 60.2 | 4.20% | 1.41%↑ |
| Gland Pharma Ltd. | Healthcare | 1,79,924 | 55.7 | 3.89% | -0.17%↓ |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 65,000 | 54.91 | 3.83% | 0.81%↑ |
| Alkem Laboratories Ltd. | Healthcare | 1,02,517 | 52.42 | 3.66% | -0.04%↓ |
| Lupin Ltd. | Healthcare | 2,60,000 | 52.29 | 3.65% | 0.75%↑ |
| Global Health Ltd. | Healthcare | 3,80,000 | 48.27 | 3.37% | 0.41%↑ |
| Cohance Lifesciences Ltd. | Healthcare | 9,00,000 | 39.99 | 2.79% | -0.00%↓ |
| Caplin Point Laboratories Ltd. | Healthcare | 1,65,000 | 38.37 | 2.68% | -0.34%↓ |
| Ipca Laboratories Ltd. | Healthcare | 1,89,056 | 36.45 | 2.54% | -0.27%↓ |
| Jupiter Life Line Hospitals Ltd. | Healthcare | 12,50,000 | 32.14 | 2.24% | 0.16%↑ |
| Marksans Pharma Ltd. | Healthcare | 10,00,000 | 30.62 | 2.14% | -0.12%↓ |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 1,29,558 | 29.78 | 2.08% | -0.04%↓ |
| Aurobindo Pharma Ltd. | Healthcare | 1,76,850 | 29.74 | 2.08% | 0.01%↑ |
| Rainbow Childrens Medicare Ltd. | Healthcare | 2,40,000 | 29.25 | 2.04% | -0.16%↓ |
| Fortis Healthcare Ltd. | Healthcare | 3,75,000 | 28.81 | 2.01% | -0.01%↓ |
| Procter & Gamble Health Ltd. | Healthcare | 50,000 | 28.35 | 1.98% | 0.03%↑ |
1 / 3
Sector-wise Portfolio Allocation
Equity exposure by sector as a percentage of total net assets, tracked across recent portfolio dates. Identifies concentration risk and sector rotation trends in the fund's holdings.
| Sector | 31 Oct 2026 | 30 Sep 2026 | 31 Aug 2026 | 31 Jul 2026 | 30 Jun 2026 | 31 May 2026 |
|---|---|---|---|---|---|---|
| Healthcare | 97.10% | 93.12% | 93.39% | 96.35% | 94.27% | 93.67% |
| Services | 0.91% | 1.00% | 0.88% | 0.73% | 0.78% | 0.78% |
Equity Insights
A detailed look at the equity holdings of this scheme — aggregated scores on value, momentum, quality parameters along with diversification and performance analysis.
Style Analysis
Value score
29.7 / 100
Weighted average Value score is 29.7. This indicates that portfolio is relatively reasonably valued using composite of value measures.
Price Momentum score
71.7 / 100
Weighted average Price Momentum score is 71.7. This indicates that portfolio has average momentum using composite of momentum measures.
Quality score
83.6 / 100
Weighted average Quality score is 83.6. This indicates that portfolio has high quality using composite of quality measures.
QVM score
71.2 / 100
Weighted average QVM score is 71.2. This indicates that portfolio has average QVM score and hence a neutral stance is warranted.
Red Flags
Frequently Asked Questions
What are the top holdings of UTI Healthcare Fund Direct-Growth?
The top holdings of UTI Healthcare Fund Direct-Growth as of 31 Oct 2026 are Sun Pharmaceutical Industries Ltd. (7.44%), Divis Laboratories Ltd. (6.46%), Dr. Reddys Laboratories Ltd. (5.78%), Ajanta Pharma Ltd. (4.29%), Max Healthcare Institute Ltd. (4.20%). These top 5 stocks together account for 28.18% of the total portfolio. You can view the complete holdings breakdown above.
How many stocks does UTI Healthcare Fund Direct-Growth hold in its portfolio?
UTI Healthcare Fund Direct-Growth holds 47 stocks in its portfolio as of 31 Oct 2026. The fund's portfolio size reflects the fund manager's investment approach, a more concentrated portfolio indicates higher conviction bets, while a larger number of holdings suggests a more diversified strategy.
What is the sector allocation of UTI Healthcare Fund Direct-Growth?
As of 31 Oct 2026, UTI Healthcare Fund Direct-Growth's top sector allocations are Healthcare (97.10%), Services (0.91%). You can find detailed sector allocation above.
What is the equity and debt allocation of UTI Healthcare Fund Direct-Growth?
As of 31 Oct 2026, UTI Healthcare Fund Direct-Growth has 98.01% allocated to equity, and 0.03% to debt. You can also check the historical trends above.
What is the market cap allocation of UTI Healthcare Fund Direct-Growth?
As of 31 Oct 2026, UTI Healthcare Fund Direct-Growth's market cap allocation is 19.57% in large caps, 36.99% in mid caps, and 43.43% in small caps.
What is the PE ratio of UTI Healthcare Fund Direct-Growth's portfolio?
The portfolio PE ratio of UTI Healthcare Fund Direct-Growth is 41.09 as of 31 Oct 2026. The portfolio PE ratio tells you how expensive or cheap the fund's holdings are relative to their earnings.
What is the credit quality of UTI Healthcare Fund Direct-Growth?
A credit rating breakdown is not available for UTI Healthcare Fund Direct-Growth — its non-equity allocation was 0.03% as of the latest disclosure. This is common when a fund's non-equity holdings are mostly cash or short-term money market instruments, which aren't assigned a credit rating the way bonds are.
When is the latest portfolio disclosure for UTI Healthcare Fund Direct-Growth?
The latest portfolio disclosure for UTI Healthcare Fund Direct-Growth is as of 31 Oct 2026. SEBI requires all mutual funds to disclose their complete portfolio holdings on a monthly basis, typically within 10 days of the end of each month.